PROF. KEVIN GILLMANN MD PHD
KEVIN GILLMANN is an ophthalmologist, glaucoma specialist and researcher. He shares his clinical work between Geneva and London, where he is an honorary fellow of Moorfields Eye Hospital. He graduated from Newcastle University Medical School in 2013 (MBBS) and became a Fellow of the European Board of Ophthalmologists in 2018.
In 2019, he completed his residency within Professor André Mermoud’s glaucoma unit and graduated a Medical Doctorate (MD) on Minimally-Invasive Glaucoma Surgery (MIGS) from the University of Lausanne.
His research with Stanford University and the Swiss Glaucoma Research Foundation focuses primarily on minimally invasive glaucoma surgery, neuroprotection and personalised glaucoma therapies. His work was featured on the frontpage of several magazines and in high-impact journals such as Nature’s Eye and the British Journal of Ophthalmology, and received grants from the BrightFocus Foundation. With over 50 peer-reviewed articles, contributions to several book chapters and international guidelines, he was recently ranked amongst the top 0.5% glaucoma experts worldwide by ExpertScape.
Dr Gillmann is also the editor of the upcoming Elsevier textbook „The Science of Glaucoma Management”. He frequently gives lectures both nationally and internationally, including at the University of Liverpool and the University of London, where he was awarded a prize for academic achievements. Aside from his activities as a clinicians and educator, Dr Gillmann has also devoted some of his research to the study and improvement of patient experience in healthcare services. He was awarded a postgraduate certificate in Media and Medicine from Harvard Medical School, a Master of Business Administration (MBA) with distinctions from the University of London, and a Master of Architecture from the University of Paris LaVillette where he wrote a thesis on the interconnections between hospital design, patient perception and society.”
EyeTech⁴
Abstract
Artificial intelligence (AI) and big data have attracted widespread attention in recent years, with research breakthroughs showing the potential for AI to enhance care and improve patient outcomes. Ophthalmology has been particularly rapid in the adoption of AI development and glaucoma care is emerging as a pathway that may benefit from AI implementation, with a high disease burden and availability of large datasets. Whilst the potential of AI to transform patient care has become evident in recent years, they have also exposed key risks associated with AI development. Furthermore, in order for AI to be implemented, there are a number of technical considerations that must still be overcome. This presentation will explore these considerations and review some ways in which the future of glaucoma management may be transformed by AI innovations.